Berg T, Johansen L, Bergundhaugen H, Hansen L J, Reddy J K, Poulsen K
Cancer Res. 1985 Jan;45(1):226-34.
Kallikrein was identified immunohistochemically and biochemically in a transplantable pancreatic acinar cell carcinoma of the rat. The concentration of immunoreactive kallikrein in tumor homogenates was the same as in the pancreas. Kallikrein in tumor cells exists as a proenzyme and is released into blood in high concentrations. The impact of the presence of a kallikrein-producing tumor on other kallikrein-containing organs and other possibly interrelated systems was investigated. The concentration of kallikrein in the submandibular gland and pancreas of host rats was not significantly different from that of control rats. Urinary kallikrein secretion was significantly increased, although this may be a result of the high plasma glandular kallikrein concentration combined with kidney damage. The plasma concentration of kininogen, kininase, and renin was not significantly different from control rats. Rats with tumor had significantly lower blood pressure than did control animals, and blood pressure was inversely related to the concentration of glandular kallikrein in plasma. However, it was not proven that the low blood pressure was due to the high concentration of kallikrein. Nephrectomized tumor rats gave a smaller hypotensive response to kininase inhibition than was expected from their high concentration of circulating kallikrein. This may be explained by the absence of the "free kallikrein" fraction in plasma of host rats.
在大鼠可移植性胰腺腺泡细胞癌中通过免疫组织化学和生物化学方法鉴定出了激肽释放酶。肿瘤匀浆中免疫反应性激肽释放酶的浓度与胰腺中的相同。肿瘤细胞中的激肽释放酶以酶原形式存在,并以高浓度释放到血液中。研究了产生激肽释放酶的肿瘤的存在对其他含激肽释放酶的器官和其他可能相关系统的影响。宿主大鼠下颌下腺和胰腺中激肽释放酶的浓度与对照大鼠相比无显著差异。尿激肽释放酶分泌显著增加,尽管这可能是血浆中腺性激肽释放酶浓度高与肾损伤共同作用的结果。激肽原、激肽酶和肾素的血浆浓度与对照大鼠相比无显著差异。患有肿瘤的大鼠血压明显低于对照动物,且血压与血浆中腺性激肽释放酶的浓度呈负相关。然而,尚未证实低血压是由激肽释放酶的高浓度所致。肾切除的肿瘤大鼠对激肽酶抑制的降压反应比根据其循环中激肽释放酶的高浓度预期的要小。这可能是由于宿主大鼠血浆中不存在“游离激肽释放酶”部分所致。